ARDANA SIGNS AGREEMENT WITH CYTOCHEMIA TO MARKET STRIANT™ SR IN GERMANY

Striant™ SR is a mucoadhesive buccal (gum surface) testosterone replacement therapy for primary and secondary male hypogonadism (i.e. those suffering from a deficiency or absence of testosterone). Striant™ SR is the first-to-market buccal adhesive tablet and is marketed by Ardana’s own sales force in the UK, to urologists and endocrinologists. Cytochemia has considerable experience in Germany selling to the same specialists through their targeted sales force which has a strong track record in the education of physicians on product usage. Cytochemia has a strong complementary portfolio to Ardana and its product ImmuCyst, which has been on the market for 13 years, is an established agent for the treatment and prevention of superficial bladder cancer. Striant™ SR presents an excellent strategic fit with Cytochemia’s product portfolio and will be an important addition.

Cytochemia expects to launch Striant™ SR in the German market later this year. Financial terms were not disclosed but Ardana will receive an upfront payment and ongoing revenues for the supply of Striant™ SR to Cytochemia.

Dr. Maureen Lindsay, Chief Executive of Ardana, said: “As the biggest and most developed market in Europe for testosterone replacement, Germany is key for Striant™ SR. In partnering with Cytochemia we believe that the product is in the best hands to ensure a successful introduction there. Striant’s novel and efficient delivery of testosterone has received high levels of acceptance from both patients and prescribers.”

Cytochemia
Cytochemia is an independent pharmaceutical company based in Germany specializing in immuno-therapeutics from either their own product development or exclusive licence agreements. The target group for Cytochemia’s therapeutics consists of gynaecologists, oncologists and urologists. The company is primarily active in the German market but in 2000 the company founded another branch of the business in Switzerland

back to top